Apogee Therapeutics is a clinical-stage biotechnology company developing antibody therapies for inflammatory and immunology diseases. Its pipeline targets conditions such as atopic dermatitis and other type 2 inflammatory disorders with engineered biologics designed for differentiated dosing or durability. With negligible product revenue to date, value rests on advancing candidates through clinical development rather than commercial sales.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -55.3 | — |
| Q2 2025 | 0 | — | -66.1 | — |
| Q3 2025 | 0 | — | -65 | — |
| Q4 2025 | 0 | — | -69.4 | — |
| Q1 2026 | 0 | — | -74.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Repligen Corporation (RGEN), Wintrust Financial Corporation (WTFC), Leonardo DRS, Inc. (DRS), Skyworks Solutions, Inc. (SWKS), Solstice Advanced Materials, Inc. (SOLS), The Ensign Group, Inc. (ENSG)